Treating wastewater from a pharmaceutical formulation facility by biological process and ozone

Water Research

Volumn 47, Issue 13, 2013, Pages 4349-4356

  Lester, Yaal ^a   Mamane, Hadas ^a   Zucker, Ines ^a   Avisar, Dror ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Carbamazepine; Formulation facility; Ozone; Pharmaceutical; Venlafaxine

Indexed keywords

AMIDES; BIOCHEMICAL ENGINEERING; BIOCHEMICAL OXYGEN DEMAND; BIODEGRADABILITY; BIOLOGICAL WATER TREATMENT; BYPRODUCTS; DEGRADATION; EFFLUENT TREATMENT; EFFLUENTS; ORGANIC CARBON; OZONE; OZONE WATER TREATMENT; TOXICITY; WASTEWATER TREATMENT;

ACTIVATED SLUDGE SYSTEMS; BIOLOGICAL PROCESS; BIOLOGICAL TREATMENT; CARBAMAZEPINE; DEGRADATION RATE; FORMULATION FACILITY; MUNICIPAL WASTEWATER TREATMENT PLANTS; PHARMACEUTICAL FORMULATION FACILITY; RAW WASTEWATERS; VENLAFAXINE;

OZONIZATION;

CARBAMAZEPINE; ORGANIC CARBON; ORGANIC MATTER; OZONE; VENLAFAXINE;

ACTIVATED SLUDGE; BIOCHEMICAL OXYGEN DEMAND; BIODEGRADATION; CONCENTRATION (COMPOSITION); DRUG; EFFLUENT; FACILITY LOCATION; ORGANIC MATTER; OZONE; POLLUTANT REMOVAL; WASTEWATER; WATER TREATMENT;

ARTICLE; BIODEGRADABILITY; CHEMICAL OXYGEN DEMAND; DEGRADATION; DRUG CONCENTRATION; HEALTH CARE FACILITY; OZONATION; PH; PHARMACEUTICAL FORMULATION FACILITY; PRIORITY JOURNAL; SLUDGE TREATMENT; WASTE WATER MANAGEMENT; WASTE WATER TREATMENT PLANT;

ISRAEL;

EID: 84879029688     PISSN: 00431354     EISSN: 18792448     Source Type: Journal    
DOI: 10.1016/j.watres.2013.04.059     Document Type: Article

References (34)

1. Andreozzi R., Raffaele M., Nicklas P. Pharmaceuticals in STP effluents and their solar photodegradation in aquatic environment. Chemosphere 2003, 50:1319-1330.
2. APHA Standard Methods for the Examination of Water & Wastewater 2005, American Public Health Association (APHA)/American Water Works Association/Water Environment Federation, Washington, DC, USA. 21st ed.
3. Arslan Alaton I., Dogruel S., Baykal E., Gerone G. Combined chemical and biological oxidation of penicillin formulation effluent. Journal of Environmental Management 2004, 73:155-163.
4. Bahr C., Schumacher J., Ernst M., Luck F., Heinzmann B., Jekel M. SUVA as control parameter for the effective ozonation of organic pollutants in secondary effluent. Water Science and Technology 2007, 55:267-274.
5. Browner C.M., Fox J.C., Frace S., Rubin M.B., Hund F. Development Documents for Final Effluent Limitations Guidelines and Standards for the Pharmaceutical Manufacturing Point Source Category 1998, Engineering andAnalysis Division Office Science and Technology, U.S. Environmental Protection Agency, Washington, DC.
6. OH/O-) in aqueous-solution. Journal of Physical and Chemical Reference Data 1988, 17:513-886.
7. Clara M., Strenn B., Kreuzinger N. Carbamazepine as a possible anthropogenic marker in the aquatic environment: investigations on the behavior of carbamazepine in wastewater treatment and during groundwater infiltration. Water Research 2004, 38:947-954.
8. Dodd M.C., Buffle M.O., von Gunten U. Oxidation of antibacterial molecules by aqueous ozone: moiety-specific reaction kinetics and application to ozone-based wastewater treatment. Environmental Science and Technology 2006, 40:1969-1977.
9. Elovitz M.S., von Gunten U., Kaiser H.P. Hydroxyl radical/ozone ratios during ozonation processes. II. The effect of temperature, pH, alkalinity, and DOM properties. Ozone: Science & Engineering 2000, 22:123-150.
10. EPA (Environmental Protection Agency) Pharmaceutical manufacturing category effluent limitations guidelines, pretreatment standards, and new source performance standards; final rule. Federal Register 1998, 50388-50437.
11. Fick J., Soderstorm H., Lindberg R.H., Phan C., Tysklind M., Larsson D.G.J. Contamination of surface, ground and drinking water from pharmaceutical production. Environmental Toxicology and Chemistry 2009, 28:2522-2527.
12. Gasser G., Pankratov I., Elhanany S., Werner P., Gun J., Gelman F., Lev O. Field and laboratory studies of the fate and enantiomeric enrichment of venlafaxine and O-desmethylvenlafaxine under aerobic and anaerobic conditions. Chemosphere 2012, 88:98-105.
13. Greenpeace, 2004. State of community health at Medac district. Principal investigators: Singh B.C. and Dr. Murlidhar.
14. von Gunten U. Ozonation of drinking water: part I. Oxidation kinetics and product formation. Water Research 2003, 37:1443-1467.
15. Hoerger C.C., Dorr B., Schlienger C., Straub J. Environmental risk assessment for the galenical formulation of solid medicinal products at Roche Basle, Switzerland. Integrated Environmental Assessment and Management 2009, 5:331-337.
16. Hollender J., Zimmermann S.G., Koepke S., Krauss M., McArdell C.S., Ort C., Singer H., von Gunten U., di Siegrist H. Elimination of organic micropollutants in a municipal wastewater treatment plant upgraded witha full-scale post-ozonation followed by sand filtration. Environmental Science and Technology 2009, 43:7862-7869.
17. Huber M.M., Canonica S., Park G.Y., von Gunten U. Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. Environmental Science and Technology 2003, 37:1016-1024.
18. Kasprzyk-Hordern B., Kondakal V.V.R., Baker D.R. Enantiomeric analysis of drugs of abuse in wastewater by chiral liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography A 2010, 1217:4575-4586.
19. 2 advanced oxidation. Environmental Science and Technology 2012, 46:6222-6227.
20. 2. Environmental Science and Technology 2012, 46:1010-1018.
21. Larsson D.G.J., de Pedro C., Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. Journal of Hazardous Materials 2007, 148:751-755.
22. 2 advanced oxidation process. Environmental Technology 2010, 31:175-183.
23. Martinez S.B., Perez-Parra J., Suay R. Use of ozone in wastewater treatment to produce water suitable for irrigation. Water Resource Management 2001, 25:2109-2124.
24. Muñoz F., von Sonntag C. The reactions of ozone with tertiary amines including the complexing agents nitrilotriacetic acid (NTA) and ethylenediaminetetraacetic acid (EDTA) in aqueous solution. Journal of the Chemical Society, Perkin Transactions 2000, 2:2029-2033.
25. Paraskeva P., Lambert S.D., Graham N.J.D. Influence of ozonation conditions on the treatability of secondary effluent. Ozone: Science &Engineering 1998, 20:133-150.
26. Phillips P.J., Smith S.G., Kolpin D.W., Zaugg S.D., Buxton H.T., Furlong E.T., Esposito K., Stinson B. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environmental Science and Technology 2010, 44:4910-4916.
27. Robinson A.A., Belden J.B., Lydy M.J. Toxicity of fluoroquinolone antibiotics to aquatic organisms. Environmental Toxicology and Chemistry 2005, 24:423-430.
28. Santoke H., Song W., Cooper W.J., Peake B.M. Advanced oxidation treatment and photochemical fate of selected antidepressant pharmaceuticals in solutions of Suwannee River humic acid. Journal of Hazardous Materials 2012, 217-218:382-390.
29. Schumacher J., Pi Y., Jekel M. Ozonation of persistent DOC in municipal WWTP effluent for groundwater recharge. Water Science and Technology 2004, 49:305-310.
30. Staehelin J., Hoigne J. Decomposition of ozone in water-rate of initiation by hydroxide ions and hydrogen-peroxide. Environmental Science and Technology 1982, 16:676-681.
31. Turski, L.A., Stoit, A., Kruse, C.G., Vader, S., Tulp, M.T.M., 2010. N-oxides of Venlafaxine and O-Desmethylvenlafaxine as Prodrugs. US patent N° 7,696,383 B2.
32. Wert E.C., Rosario-Ortiz F.L., Snyder S.A. Effect of ozone exposure on the oxidation of trace organic contaminants in wastewater. Water Research 2009, 43:1005-1014.
33. Yao C.C.D., Haag W.R. Rate constants for direct reactions of ozone with several drinking water contaminants. Water Research 1991, 25:761-773.
34. Zimmermann S.G., Wittenwiler M., Hollender J., Krauss M., Ort C., Siegrist H., von Gunten U. Kinetic assessment and modeling of an ozonation step for full-scale municipal wastewater treatment: micropollutant oxidation, by-product formation and disinfection. Water Research 2011, 45:605-617.